삼성서울병원

Ko En

Ahn, Myung Ju M.D

TITLE
Professor, Department of Hematology & Oncology, Samsung Medical Center
Treament Schedule 07 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM
Treament Schedule 08 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
SAT
29
SUN
30
MON
31
AM
PM

Medical School

Hanyang University College of Medicine

Specialty Training

Fellowship   Asan Medical Center
Residency   Hanyang University Hospital
Internship   Hanyang University Hospital

Other Education

Master: Hanyang University Graduate School
Ph.D: Hanyang University Graduate School
Postdoctoral fellowship: Memorial Sloan Kettering Cancer Center, USA

Clinical & Research Interests

Medical Oncology (Lung cancer, Head and neck cancer, Esophageal cancer)

Participation in Academic Societies
and Research

Member, Korean Medical Association
Member, Korean Association of Internal Medicine
Member, Korean Association of Oncology
Member, Korean Association for Cancer Research
Member, American Society of Oncology
Member, International Association Society of Lung Cancer
Member, European Society of Medical Oncology
Member, Korean Association of Clinical Oncology
Member, Korean Association Society of Lung Cancer
Member, Korean Head and Neck Cancer Society

Selected Publications

  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study Ahn1, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC
    View PubMed
  • LANCET ONCOL 2019 10.1016/S1470-2045(19)30626-6 Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Kato1, K; Cho, BC; Takahashi, M; Okada, M; Lin, CY; Chin, K; Kadowaki, S; Ahn, MJ; Hamamoto, Y; Doki, Y; Yen, CC; Kubota, Y; Kim, SB; Hsu, CH; Holtved, E; Xynos, I; Kodani, M; Kitagawa, Y
    View PubMed
  • CANCER 2019 10.1002/cncr.32503 Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer Papadimitrakopoulou1, VA; Han, JY; Ahn, MJ; Ramalingam, SS; Delmonte, A; Hsia, TC; Laskin, J; Kim, SW; He, Y; Tsai, CM; Hida, T; Maemondo, M; Kato, T; Jenkins, S; Patel, S; Huang, XN; Laus, G; Markovets, A; Thress, KS; Wu, YL; Mok, T
    View PubMed
  • J THORAC ONCOL 2019 10.1016/j.jtho.2019.06.010 Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC Antonia1, SJ; Balmanoukian, A; Brahmer, J; Ou, SHI; Hellmann, MD; Kim, SW; Ahn, MJ; Kim, DW; Gutierrez, M; Liu, SV; Schoffski, P; Jager, D; Jamal, R; Jerusalem, G; Lutzky, J; Nemunaitis, J; Calabro, L; Weiss, J; Gadgeel, S; Bhosle, J; Ascierto, PA; Rebelatto, MC; Narwal, R; Liang, MN; Xiao, F; Antal, J; Abdullah, S; Angra, N; Gupta, AK; Khleif, SN; Segal, NH
    View PubMed
  • J CLIN ONCOL 2019 10.1200/JCO.19.00934 Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study Garon1, EB; Hellmann, MD; Rizvi, NA; Carcereny, E; Leighl, NB; Ahn, MJ; Eder, JP; Balmanoukian, AS; Aggarwal, C; Horn, L; Patnaik, A; Gubens, M; Ramalingam, SS; Felip, E; Goldman, JW; Scalzo, C; Jensen, E; Kush, DA; Hui, R
    View PubMed